Overview of the Pharmacological Properties of Daltroban, a Thromboxane A 2 /Prostanoid‐Receptor Partial Agonist
1998; Wiley; Volume: 16; Issue: 3 Linguagem: Inglês
10.1111/j.1527-3466.1998.tb00358.x
ISSN1527-3466
AutoresGareth W. John, Françis C. Colpaert, Jean Pierre Valentin,
Tópico(s)Hormonal Regulation and Hypertension
ResumoCardiovascular Drug ReviewsVolume 16, Issue 3 p. 264-287 Free Access Overview of the Pharmacological Properties of Daltroban, a Thromboxane A2/Prostanoid-Receptor Partial Agonist Gareth W. John, Corresponding Author Gareth W. John Centre de Recherche Pierre Fabre, Castres Cédex, FranceAddress correspondence and reprint request to Dr. G. W. John, Division of Cardiovascular Diseases, Centre de Recherche Pierre Fabre, 17 avenue Jean Moulin, 81106 Castres Cédex, France. Fax: 33-5-63-71-43-63.Search for more papers by this authorFrancis C. Colpaert, Francis C. Colpaert Centre de Recherche Pierre Fabre, Castres Cédex, FranceSearch for more papers by this authorJean Pierre Valentin, Jean Pierre Valentin Centre de Recherche Pierre Fabre, Castres Cédex, FranceSearch for more papers by this author Gareth W. John, Corresponding Author Gareth W. John Centre de Recherche Pierre Fabre, Castres Cédex, FranceAddress correspondence and reprint request to Dr. G. W. John, Division of Cardiovascular Diseases, Centre de Recherche Pierre Fabre, 17 avenue Jean Moulin, 81106 Castres Cédex, France. Fax: 33-5-63-71-43-63.Search for more papers by this authorFrancis C. Colpaert, Francis C. Colpaert Centre de Recherche Pierre Fabre, Castres Cédex, FranceSearch for more papers by this authorJean Pierre Valentin, Jean Pierre Valentin Centre de Recherche Pierre Fabre, Castres Cédex, FranceSearch for more papers by this author First published: 02 April 2007 https://doi.org/10.1111/j.1527-3466.1998.tb00358.xCitations: 1AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Abe T, Takeuchi K, Takahashi N, Tsutsumi E, Taneyama Y, Abe K. Rat kidney thromboxane A2 receptor: Molecular cloning, signal transduction and intrarenal expression localization. J Clin Invest 1995: 96: 657–664. 10.1172/JCI118108 CASPubMedWeb of Science®Google Scholar 2 Allan CJ, Higashiura K, Martin M, et al. Characterization of the cloned HEL cell thromboxane A2 receptor: Evidence that the affinity state can be altered by Gα13 and Gαq. J Pharmacol Exp Ther 1996; 277: 1132–1139. CASPubMedWeb of Science®Google Scholar 3 Al-Wathiqui MH, Hartmann JC, Brooks HL, Gross GJ, Warltier DC. Cyclical carotid artery flow reduction in conscious dogs: Effect of a new thromboxane receptor antagonist. Am Heart J 1988; 116: 1482–1487. 10.1016/0002-8703(88)90732-6 CASPubMedWeb of Science®Google Scholar 4 Aoki N, Lefer AM. Protective effects of thromboxane receptor blockade in splanchnic artery occlusion shock. Meth Find Exp Clin Pharmacol 1988; 10: 413–418. CASPubMedWeb of Science®Google Scholar 5 Arita H, Nakano T, Hanasaki K. Thromboxane A2: Its generation and role in platelet activation. Prog Lipid Res 1989: 19: 711–734. Google Scholar 6 Arner M, Hogestatt ED, Uski TK. Characterization of contraction-mediating prostanoid receptors in human hand versus effects of the thromboxane receptor antagonists BM 13.505 and AH 23.848. Acta Physiol Scand 1991: 141: 79–86. 10.1111/j.1748-1716.1991.tb09047.x CASPubMedWeb of Science®Google Scholar 7 Bertolino F, Valentin JP, Maffre M, Bessac AM, John GW. TxA2 receptor activation elicits organ specific increases in microvascular permeability in the rat. Am J Physiol 1995; 268: R366–R374. CASPubMedWeb of Science®Google Scholar 8 Bertolino F, Valentin JP, Maffre M, Jover B, Bessac AM, John GW. Prevention of thromboxane A2 receptor-mediated pulmonary hypertension by a nonpeptide angiotensin II type I receptor antagonist. J Pharmacol Exp Ther 1994; 268: 747–752. CASPubMedWeb of Science®Google Scholar 9 Bertolino F, Valentin JP, Patoiseau JF, Rieu JP, Colpaert FC, John GW. Evidence for partial agonist properties of daltroban (BM 13,505) at TP receptors in the anaesthetized open-chest rat. Naunyn-Schmiedebergs Arch Pharmacol 1997; 356: 462–466. 10.1007/PL00005077 CASPubMedWeb of Science®Google Scholar 10 Bertolino F, Valentin JP, Maffre M, et al. Intrinsic activity of the non-prostanoid thromboxane A2-receptor antagonist, daltroban (BM 13,505), in human platelets in vitro and in the rat vasculature in vivo. Br J Pharmacol 1995; 115: 210–216. 10.1111/j.1476-5381.1995.tb16341.x CASPubMedWeb of Science®Google Scholar 11 Besse T, Gustin T, Claeys N, Schroeyers P, Lambotte L. Effect of PGI2 and thromboxane antagonist on liver ischemic injury. Eur Surg Res 1989; 21: 213–217. 10.1159/000129026 CASPubMedWeb of Science®Google Scholar 12 Bhat AM, Sachs H, Osborne JA, Lefer AM. Protective effect of the specific thromboxane receptor antagonist, BM-13505, in reperfusion injury following acute myocardial ischemia in cats. Am Heart J 1989: 117: 799–803. 10.1016/0002-8703(89)90615-7 CASPubMedWeb of Science®Google Scholar 13 Bitterman H, Yanagisawa A, Lefer AM. Beneficial actions of thromboxane receptor antagonism in hemorrhagic shock. Circ Shock 1986: 20: 1–11. CASPubMedWeb of Science®Google Scholar 14 Brass L, Shaller CC, Belmonte EJ. Inositol 1,4,5-triphosphate-induced granule secretion in platelets. Evidence that the activation of phospholipase C mediated by platelet thromboxane receptors involves a guanine nucleotide binding protein-dependent mechanism distinct from that of thrombin. J Clin Invest 1987: 79: 1269–1275. 10.1172/JCI112947 CASPubMedWeb of Science®Google Scholar 15 Brezinski ME, Lefer DJ, Bowker B, Lefer AM. Thromboxane-induced red blood cell lysis. Prostaglandins 1987: 33: 75–84. 10.1016/0090-6980(87)90306-6 CASPubMedWeb of Science®Google Scholar 16 Brittain RT, Boutal L, Carter MC, et al. AH23848: A thromboxane receptor-blocking drug that can clarify the pathophysiological role of thromboxane A2. Circulation 1985; 72: 1208–1218. 10.1161/01.CIR.72.6.1208 CASPubMedWeb of Science®Google Scholar 17 Brooks DP, Contino LC, Trinza W. Effect of enalapril or the thromboxane-receptor antagonist, daltroban, in rats with subtotal renal ablation. J Pharmacol Exp Ther 1990; 253: 119–123. CASPubMedWeb of Science®Google Scholar 18 Bunce KT, Spraggs CF. Stimulation of chloride secretion by U-46619 in guinea pig isolated gastric mucosa is mediated by thromboxane receptors. Br J Pharmacol 1987: 91: 319P. Google Scholar 19 Bush LR, Smith SG. Antagonism of U46619-induced aggregation of human and canine platelets by four TxA2 receptor antagonists. Thromb Res 1986: 44: 377–389. 10.1016/0049-3848(86)90012-5 CASPubMedWeb of Science®Google Scholar 20 Coleman DJ, Coleman RA, Cross SE, Naylor IL. Prostanoid-induced contraction of myofibroblasts: Effect of the thromboxane (TP) receptor antagonist, GR32191. Br J Pharmacol 1989; 96: 65P. PubMedWeb of Science®Google Scholar 21 Coleman RA, Humphrey PP, Kennedy I, Levy GP, Lumley P. Comparisons of the actions of U-46619, a stable prostaglandin H2 analogue, with those of prostaglandin H2 and thromboxane A2 on some isolated smooth muscle preparations. Br J Pharmacol 1981: 73: 773–778. 10.1111/j.1476-5381.1981.tb16814.x CASPubMedWeb of Science®Google Scholar 22 Coleman RA, Kennedy I. Characterisation of the prostanoid receptors mediating contraction of guinea pig isolated trachea. Prostaglandins 1985; 29: 363–375. 10.1016/0090-6980(85)90096-6 CASPubMedWeb of Science®Google Scholar 23 Coleman RA, Sheldrick RLG. Prostanoid-induced contraction of human bronchial smooth muscle is mediated by TP receptors. Br J Pharmacol 1989: 96: 688–692. 10.1111/j.1476-5381.1989.tb11869.x CASPubMedWeb of Science®Google Scholar 24 Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: Properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 1994: 46: 205–229. CASPubMedWeb of Science®Google Scholar 25 Coleman RA. Methods in prostaglandin receptor classification. In: C Benedetto, RG McDonald-Gibson, S Nigam, TF Slater, eds. Prostaglandins and related substances—A practical approach, Oxford UK : IRL Press, 1987: 267–303. Google Scholar 26 D'Angelo DD, Davis MG, Ali S, Dorn GW II. Cloning and pharmacologic characterization of a thromboxane A2 receptor from K562 (human chronic myelogenous leukemia) cells. J Pharmacol Exp Ther 1994; 271: 1034–1041. CASPubMedWeb of Science®Google Scholar 27 Davi G, Alessandrini P, Mezzetti A, et al. In vivo formation of 8-epi-prostaglandin F2α is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997: 17: 3230–3235. 10.1161/01.ATV.17.11.3230 CASPubMedWeb of Science®Google Scholar 28 Davis-Bruno KL, Halushka PV. Molecular pharmacology and therapeutic potential of thromboxane A2-receptor antagonists. Adv Drug Res 1994: 25: 173–202. CASGoogle Scholar 29 Dorn GW, Becker MV, Davis MG. Dissociation of the contractile and hypertrophic effects of vasoconstrictor prostanoids in vascular smooth muscle. J Biol Chem 1992; 267: 24897–24905. 10.1016/S0021-9258(18)35848-4 CASPubMedWeb of Science®Google Scholar 30 Dorn GW, Liel N, Trask JL, Mais DE, Assey ME, Halushka PV. Increased platelet thromboxane A2 prostaglandin H2 receptors in patients with acute myocardial infarction. Circulation 1990: 81: 212–218. 10.1161/01.CIR.81.1.212 PubMedWeb of Science®Google Scholar 31 Dubé GP, Kurtz WL, Mais EM, Brune KA, Rinkema LE, Jakubowski JA. In vitro profile of a novel thromboxane A2-antagonist in platelets and arteries. Circulation 1989: 80: II-439. Google Scholar 32 Dusting GJ, Moncada S, Vane JR. Prostaglandins, their intermediates and precursors: Cardiovascular actions and regulatory roles in normal and abnormal circulatory systems. Prog Cardiovasc Dis 1979; 21: 405–430. 10.1016/0033-0620(79)90024-0 CASPubMedWeb of Science®Google Scholar 33 Dyson MC, Kadowitz JP. Influence of SK&F 96148 on thromboxane-mediated responses in the airways of the cat. Eur J Pharmacol 1991; 197: 17–25. 10.1016/0014-2999(91)90359-X CASPubMedWeb of Science®Google Scholar 34 Farber NE, Pieper GM, Gross JG. Lack of involvement of thromboxane A2 in postischemic recovery of stunned canine myocardium. Circulation 1988: 78: 450–461. 10.1161/01.CIR.78.2.450 CASPubMedWeb of Science®Google Scholar 35 Gniwotta C, Morrow JD, Roberts LJ, Kühn H. Prostaglandin F2-like compounds, F2-isoprostanes, are present in increased amounts in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1997; 17: 3236–3241. 10.1161/01.ATV.17.11.3236 CASPubMedWeb of Science®Google Scholar 36 Gresele P, Deckmyn H, Nenci GG, Vermylen J. Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders. Trends Pharmacol Sci 1991; 12: 158–163. 10.1016/0165-6147(91)90533-X CASPubMedWeb of Science®Google Scholar 37 Griswold DE, Egan JW, Earl CQ, Hillegas LM, Marshall PJ, Smith III EF. Reduction of myocardial damage and polymorphonuclear leukocyte accumulation following coronary artery occlusion and reperfusion by the thromboxane receptor antagonist BM 13.505. Prostaglandins Clin Res 1989: 161–165. CASGoogle Scholar 38 Hall SE. Thromboxane A2-receptor antagonists. Med Res Rev 1991; 11: 503–579. 10.1002/med.2610110504 CASPubMedWeb of Science®Google Scholar 39 Halushka PV, Mais DV. Basic and clinical pharmacology of thromboxane. Drugs Today 1989; 25: 383–393. CASGoogle Scholar 40 Halushka PV. Pharmacology of thromboxane A2–receptor antagonists. Z. Kardiol 1989; 78: 42–47. CASPubMedWeb of Science®Google Scholar 41 Halushka PV, Alan CJ, Davis-Bruno KL. Thromboxane A2 receptors. J. Lipid Mediators Cell Sign 1995; 12: 361–378. 10.1016/0929-7855(95)00023-J CASPubMedWeb of Science®Google Scholar 42 Hamberg M, Svensson J, Samuelsson B. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Nat Acad Sci USA 1975; 72: 2994–2998. 10.1073/pnas.72.8.2994 CASPubMedWeb of Science®Google Scholar 43 Hanasaki K, Arita H. Characterization of a new compound, S-145, as a specific TxA2-receptor antagonist in platelets. Thromb Res 1988: 50: 365–376. 10.1016/0049-3848(88)90266-6 CASPubMedWeb of Science®Google Scholar 44 Hanasaki K, Nakano T, Arita H. Receptor-mediated mitogenic effect of thromboxane A2 in vascular smooth muscle cells. Biochem Pharmacol 1990; 40: 2535–2542. 10.1016/0006-2952(90)90096-4 CASPubMedWeb of Science®Google Scholar 45 Hedberg A, Hall SE, Ogletree ML, Harris DNH, Lieu ECK. Characterization of [5,6-3H]SQ 29,548 as a high-affinity radioligand, binding to thromboxane A2/protaglandin H2 receptors in human platelets. J Pharmacol Exp Ther 1988; 245: 706–792. PubMedWeb of Science®Google Scholar 46 Hirata M, Hayashi Y, Ushikubi F, et al. Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature 1991; 349: 617–620. 10.1038/349617a0 CASPubMedWeb of Science®Google Scholar 47 Hirata T, Ushikubi F, Kakizuka A, Okuma M, Narumiya S. Two thromboxane A2–receptor isoforms in human platelets. J Clin Invest 1996; 97: 949–956. 10.1172/JCI118518 CASPubMedWeb of Science®Google Scholar 48 Hood JS, Nossaman BD, Ibrahim IN, McMahon TJ, Babycos CR, Kodowitz PJ. Daltroban blocks thromboxane responses in the pulmonary vascular bed of the cat. J Appl Physiol 1992; 72: 2305–2310. CASPubMedWeb of Science®Google Scholar 49 Humphrey PPA, Lumley P, White BP. The agonist action of AH23848 at guinea pig vascular and airways smooth muscle TP receptors in vivo. Br J Pharmacol 1986; 89: 820P. Google Scholar 50 Humphrey PPA, Hallet P, Hornby P, Walis CJ, Collington EW, Lumley P. Pathophysiological action of thromboxane A2 and their pharmacological antagonism by thromboxane receptor blockade with GR 32191. Circulation 1990; 81: 142–152. Google Scholar 51 Hunt JA, Merritt JE, MacDermot J, Keen M. Characterization of the thromboxane receptor mediating prostacyclin release from cultured endothelial cells. Biochem Pharmacol 1992; 43: 1747–1752. 10.1016/0006-2952(92)90705-N CASPubMedWeb of Science®Google Scholar 52 Janssens WJ, Deckmyn H, Gresele P, Vermylen J. BM13.177 selectively inhibits endoperoxide analogue induced vascular contractions. Arch Int Pharmacodyn 1985; 276: 28–34. CASPubMedWeb of Science®Google Scholar 53 John GW, Valentin JP. Analysis of the pulmonary hypertensive effects of the isoprostane derivative, 8-iso-PGF2α in the rat. Br J Pharmacol 1997; 122: 899–905. 10.1038/sj.bjp.0701441 CASPubMedWeb of Science®Google Scholar 54 Jourdan KB, Evans TW, Mitchell JA. Production of the isoprostane, 8-iso-PGF2α by human pulmonary artery smooth muscle cells is cyclooxygenase-2-dependent. Br J Pharmacol 1998: 123: 161. Google Scholar 55 Kao J, Dulik D, Joseph G, et al. Comparative disposition and metabolism of sulotroban and daltroban in rats and dogs. Eur J Pharmacol 1990; 183: 1880–1881. 10.1016/0014-2999(90)92217-7 Web of Science®Google Scholar 56 Kaplan R, Aynedjian HS, Schlondorff D, Bank N. Renal vasoconstriction caused by short-term cholesterol feeding is corrected by thromboxane antagonist or probucol. J Clin Invest 1990; 86: 1707–1714. 10.1172/JCI114895 CASPubMedWeb of Science®Google Scholar 57 Kakushi H, Shike T, Arita H, Uchida K. Effect of (+)-S-1452 calcium salt dihydrate, an orally active antagonist of the thromboxane A2/prostaglandin H2 endoperoxide receptor, on platelet aggregation. Folia Pharmacol Jpn 1991; 98: 113–120. 10.1254/fpj.98.2_113 CASPubMedWeb of Science®Google Scholar 58 Kenakin T. Pharmacologic analysis of drug receptor interaction. New York : Raven Press NY, 1993: 1–277. Google Scholar 59 Kitanaka J, Hashimoto H, Sugimoto Y, et al. cDNA cloning of a thromboxane A2 receptor from rat astrocytes. Biochim Biophys Acta 1995; 1265: 220–223. 10.1016/0167-4889(94)00225-4 PubMedWeb of Science®Google Scholar 60 Klein T, Reutter F, Schweer H, Seyberth HW, Niising RM. Generation of the isoprostaine 8-epiprostaglandin F2α in vitro and in vivo via the cyclooxygenases. J Pharmacol Exp Ther 1997; 282: 1658–1665. CASPubMedWeb of Science®Google Scholar 61 Klimm JL, Klocsewiak MA, Lindon J. Effects of free and macromolecular-bound TXA2 receptor-antagonist BM 13.505 on U46619-induced platelet aggregation. Prostaglandins 1993; 46: 27–36. 10.1016/0090-6980(93)90060-K CASPubMedWeb of Science®Google Scholar 62 Knezevic I, Borg C, Le Breton GC. Identification of Gq as one of the G-proteins which copurify with human platelet thromboxane A2/prostaglandin H2 receptors. J Biol Chem 1993; 268: 26011–26017. CASPubMedWeb of Science®Google Scholar 63 Kromer B. The pathophysiology of the F2-isoprostanes within the coronary circulation. PhD. Thesis, University of London 1998: 1–237. Google Scholar 64 Kromer BM, Tippins JR. Coronary artery constriction by the isoprostane 8-epi prostaglandin F2α. Br J Pharmacol 1996; 119: 1276–1280. 10.1111/j.1476-5381.1996.tb16033.x CASPubMedWeb of Science®Google Scholar 65 Le Breton GC, Lim CT, Vaidya CM, Ventron DL. Thromboxane A2/prostaglandin H2-receptor antagonists. Meth Enzymol 1990; 187: 406–414. 10.1016/0076-6879(90)87047-7 PubMedWeb of Science®Google Scholar 66 Lefer A, Darius H. A pharmacological approach to thromboxane receptor antagonism. Fed Proc 1987; 46: 144–148. CASPubMedWeb of Science®Google Scholar 67 Lefer AM. Daltobran (BM-13.505)—A highly specific, potent thromboxane receptor antagonist. Drugs Future 1988; 13: 999–1005. 10.1358/dof.1988.013.11.67841 Google Scholar 68 Lefer AM. Comparison of the actions of thromboxane receptor antagonists in biological systems. Drugs Today 1985; 21: 283–291. CASGoogle Scholar 69 Lefer DJ, Lefer AM. Thromboxane receptor antagonists block the bronchoconstrictor effect of thromboxane-mimetics in cat pulmonary tissue. Med Sci Res 1987; 15: 707–708. CASWeb of Science®Google Scholar 70 Lefer DJ, Mentley RK, Lefer AM. Protective effects of a new specific thromboxane antagonist in arachidonate-induced sudden death. Arch Int Pharmacodyn Ther 1987: 287: 89–95. CASPubMedWeb of Science®Google Scholar 71 Levitt MA. Dryjski M, Tluczek J, Bjornsson TD. Evaluation of a prostacyclin analog, iloprost, and a thromboxane A2-receptor antagonist, daltroban, in experimental intimai hyperplasia. Prostaglandins 1991; 41: 1–6. 10.1016/0090-6980(91)90099-2 CASPubMedWeb of Science®Google Scholar 72 Liel N, Nathan I, Yermiyahu T, et al. Increased platelet thromboxane A2/prostaglandin H2 receptors in patients with pregnancy-induced hypertension. Thromb Res 1993; 70: 205–210. 10.1016/0049-3848(93)90126-9 CASPubMedWeb of Science®Google Scholar 73 Löbel P, Schrör E, Schrör K. Beneficial effects of a thromboxane receptor antagonist (BM 13.505) on platelet hyperreactivity and thromboxane formation in cholesterol-fed rabbits. Biomed Biochem Acta 1988: 47: S86–S89. CASPubMedWeb of Science®Google Scholar 74 Lumley P, Seager K, White B. The TP receptor-blocking drugs GR32191 and BM13.177 have a differential profile of action on vascular smooth muscle. Br J Pharmacol 1988; 95: 685P. Google Scholar 75 MacIntyre, DE. Platelet prostaglandin receptors. In: J. Gordon ed. Platelets in biology and pathology. Amsterdam : Elseiver, 1981: 211–246. Google Scholar 76 Mallat Z, Philip I, Lebret M, Chatel D, Maclouf J, Tedgui A. Elevated levels of 8-iso-prostaglandin F2α in pericardial fluid of patients with heart failure. Circulation 1998; 97: 1536–1539. 10.1161/01.CIR.97.16.1536 CASPubMedWeb of Science®Google Scholar 77 Malmsten C. Some biological effects of prostaglandin analogs. Life Sci 1976; 18: 169–176. 10.1016/0024-3205(76)90021-7 CASPubMedWeb of Science®Google Scholar 78 Mayeux PR, Shah SV. Glomerular thromboxane A2/prostaglandin H2 receptors: Characterization and effect of adriamycin induced nephrotic syndrome. Biochim Biophys Acta 1993; 1181: 148–154. 10.1016/0925-4439(93)90104-9 CASPubMedWeb of Science®Google Scholar 79 Meade CJ, Muacevic G, Ward P, Soyka R. Pulmonary pharmacology of DT-TX 30 SE, a potent selective combined thromboxane synthethase inhibitor and receptor antagonist, in guinea pigs. Jpn J Pharmacol 1996; 71: 119–127. 10.1254/jjp.71.119 CASPubMedWeb of Science®Google Scholar 80 Mehta JL, Nichols WW. The potential role of thromboxane inhibitors in preventing myocardial ischaemic injury. Drugs 1990; 40: 657–665. 10.2165/00003495-199040050-00002 CASPubMedWeb of Science®Google Scholar 81 Metz J, Wolf O, Schmeltz A, Pill J, Stegmeier KH, Hartig F. Atherosclerosis in the aorta of hypercholeresterolemic rabbits and the influence of daltroban. Exp Pathol 1991; 41: 57–78. 10.1016/S0232-1513(11)80001-0 CASPubMedWeb of Science®Google Scholar 82 Miki I, Kase H, Ishii A. Differences in activities of thromboxane A2-receptor antagonist in smooth muscle cells. Eur J Pharmacol 1992; 227: 199–204. 10.1016/0922-4106(92)90128-I CASPubMedWeb of Science®Google Scholar 83 Miki I, Kase H, Ishii A. Differences in activities of thromboxane A2–receptor antagonists, KW-3635 and BM-13505, in vascular smooth muscel cells. Eur J Pharmacol 1992;(Suppl): 228P. Google Scholar 84 Misra RN. Recent progress in the clinical development of thromboxane A2-receptor antagonists. Exp Opin Invest Drugs 1994; 3: 469–480. 10.1517/13543784.3.5.469 CASGoogle Scholar 85 Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263: 663–665. 10.1038/263663a0 CASPubMedWeb of Science®Google Scholar 86 Morinelli TA. Halushka PV. Thromboxane A2/Prostaglandin H2 receptors. Characterization and antagonism. Trends Cardiovasc Med 1991; 1: 157–161. 10.1016/1050-1738(91)90021-6 CASPubMedWeb of Science®Google Scholar 87 Morrow JD, Awad JA, Kato T, et al. Formation of novel non-cyclooxygenase derived prostanoids (F2 isoprostanes) in carbon tetrachloride hepatotoxicity. An animal model of lipid peroxidation. J Clin Invest 1992; 90: 2502–2507. 10.1172/JCI116143 CASPubMedWeb of Science®Google Scholar 88 Morrow JD, Harris TM, Roberts LJT. Non-cyclooxygenase oxidative formation of a series of novel prostaglandins: Analytical ramifications for measurement of eicosanoids. Anal Biochem 1990; 184: 1–10. 10.1016/0003-2697(90)90002-Q CASPubMedWeb of Science®Google Scholar 89 Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJT. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Nat Sci USA 1990; 87: 9383–9387. 10.1073/pnas.87.23.9383 CASPubMedWeb of Science®Google Scholar 90 Muck S, Weber AA, Meyer-Kirchrath J, Schrör K. The bovine thromboxane A2 receptor: Molecular clonging, expression, and functional characterization. Naunyn-Schmiedeberg's Arch Pharmacol 1998; 357: 10–16. 10.1007/PL00005132 CASPubMedWeb of Science®Google Scholar 91 Namba T, Sugimto Y, Hirata M, et al. Mouse thromboxane A2 receptor: cDNA cloning, expression, and northern blot analysis. Biochem Biophys Res Commun 1992; 184: 1197–1203. 10.1016/S0006-291X(05)80009-9 CASPubMedWeb of Science®Google Scholar 92 Namba T, Narumiya S. Thromboxane A2 receptor: Structure, function, and tissue distribution. Nippon Rinsho 1993; 51: 233–240. CASPubMedGoogle Scholar 93 Nicki J, Haarmann W, Ballhause H, et al. New N-arylethyl-arene sulphonamino derivatives—Useful for treating and preventing thromboembolism, arterioscleroris, and metastases. Eur Patent Appl 1986; EP0194548A. Google Scholar 94 Nourooz-Zadeh J, Änggård EE. Plasma 8-epi PGF2α levels in health and disease. Adv Exp Biol Med 1997; 433: 189–192. 10.1007/978-1-4899-1810-9_39 CASPubMedWeb of Science®Google Scholar 95 Normann P, Cuthbert NJ, McKenniff MG, Gardiner JP. The thromboxane receptors of rat and guinea pig lung. Eur J Pharmacol 1992; 229: 171–178. 10.1016/0014-2999(92)90552-F CASPubMedWeb of Science®Google Scholar 96 Nossaman BD, McMahon TJ, Ragheb MS, et al. Blockade of thromboxane/endoperoxide receptor-mediated responses in the pulmonary vascular bed of the cat by solutroban. Eur J Pharmacol 1992; 213: 1–7. 10.1016/0014-2999(92)90225-S CASPubMedWeb of Science®Google Scholar 97 Nüsing RM, Hirata M, Kakizuka A, Eki T, Ozawa K, Narumiya S. Characterization and chromosomal mapping of the human thromboxane A2-receptor gene. J Biol Chem 1993; 268: 23253–23259. Google Scholar 98 Ogletree M. Overview of physiological and pathophysiological effects of thromboxane A2. Fed Proc 1987; 46: 133–148. CASPubMedWeb of Science®Google Scholar 99 Ogletree ML, Harris DN, Greenberg R, Haslanger MF, Nakane M. Pharmacological actions of SQ 29,548, a novel selective thromboxane antagonist. J Pharmacol Exp Ther 1985; 234: 435–441. CASPubMedWeb of Science®Google Scholar 100 Ogletree ML, Harris DN, Schumacher WA, Webb ML, Misra RN. Pharmacological profile of BMS 180,291: A potent, long-acting, orally active thromboxane A2/prostaglandin endoperoxide receptor antagonist. J Pharmacol Exp Ther 1993; 264: 570–578. CASPubMedWeb of Science®Google Scholar 101 Ogletree ML, Allen GT. Interspecies differences in thromboxane receptors: Studies with thromboxane receptor antagonists in rat and guinea pig smooth muscles. J Pharmacol Exp Ther 1992; 260: 789–794. CASPubMedWeb of Science®Google Scholar 102 Osborne JA, Lefer AM. Cardioprotective actions of thromboxane receptor antagonism in ischemic atherosclerotic rabbits. Am J Physiol 1988; 255: H318–H324. CASPubMedWeb of Science®Google Scholar 103 Osborne JA, Lento PH, Siegfried MR, Stahl GL, Fusman B, Lefer AM. Cardiovascular effects of acute hypercholesterolemia in rabbits: reversal with lovastatin treatment. J Clin Invest 1989; 83: 465–473. 10.1172/JCI113905 CASPubMedWeb of Science®Google Scholar 104 Pakala R, Willerson JT, Benedict CR. Effect of serotonin, thromboxane A2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation 1997; 96: 2280–2286. 10.1161/01.CIR.96.7.2280 CASPubMedWeb of Science®Google Scholar 105 Patrignani P, Santini G, Panara MR, et al. Induction of prostaglandin endoperoxide synthase-2 in human monocytes associated with cyclooxygenase dependent F2 isoprostane formation. Br J Pharmacol 1996; 118: 1285–1293. 10.1111/j.1476-5381.1996.tb15535.x CASPubMedWeb of Science®Google Scholar 106 Patrono C, Fitzgerald GA. Isoprostanes: Potential markers of oxidant stress in atherothrombotic diseases. Arterioscler Thromb Vase Biol 1997; 17: 2309–2315. 10.1161/01.ATV.17.11.2309 CASPubMedWeb of Science®Google Scholar 107 Patscheke H. Thromboxane A2/Prostaglandin H2–receptor antagonists, a new therapeutic principle. Stroke 1990; 21: 139–142. Web of Science®Google Scholar 108 Patscheke H, Homberger W, Stegmeier K. Blockade of the human platelet thromboxane A2 receptor by 4(2-[p-chlorobenzene sulphonylamino]-ethylbenzene acetic acid (BM 13.505). Int Conf Leukotrienes Prostanoids Health DisOct 20–25, 1985, Tel-Aviv Revoho. Google Scholar 109 Patscheke H, Stegmeier K, Homberger W, Staiger C, Neugebauer G. Inhibition of platelet activation by the novel thromboxane receptor antagonist BM13.505. Thromb Haemost 1987; 58: 182. Web of Science®Google Scholar 110 Pill J, Schmelz A, Wolf O, Pavlov P, Metz J. Effects of daltroban on cellular cholesterol and atherosclerosis in rabbits. Eur J Pharmacol 1990; 183: 1327. 10.1016/0014-2999(90)94444-3 Web of Science®Google Scholar 111 Pill J, Metz J, Stegmeier K, Hartig F. Effects of daltroban, a thromboxane (Tx) A2 receptor antagonist, on lipid metabolism and atherosclerosis. Agents Actions Suppl 1992; 37: 107–113. CASPubMedWeb of Science®Google Scholar 112 Pill J, Wolf O, Schmelz A, Stegmeier K, Metz J. Investigation of the antiatherosclerotic effect of the thromboxane A, receptor antagonist daltroban. Z Kardiol 1990; 79: 155–160. CASPubMedWeb of Science®Google Scholar 113 Piper PJ, Vane JR. Release of additional factors of anaphylaxis and its antagonism by anti-inflammatory drugs. Nature 1969; 223: 29–35. 10.1038/223029a0 CASPubMedWeb of Science®Google Scholar 114 Pollock W, Amstrong RA, Brydon LJ, Jones RL, Macintyre DE. Thromboxane-induced phosphatidate formation in human platelets. Relationship to receptor occupancy and to changes in cytosolic free calcium. Biochemistry 1984: 219: 833–842. 10.1042/bj2190833 CASPubMedWeb of Science®Google Scholar 115 Prasad S, Willerson JT, Benedict CR. Effect of serotonin, thromboxane A2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation 1997; 96: 2280–2286. 10.1161/01.CIR.96.7.2280 PubMedWeb of Science®Google Scholar 116 Pratico D, Fitzgerald GA. Generation of 8-epi prostaglandin F2 alpha by human monocytes. Discriminate production by reactive oxygen species and prostaglandin endoperoxide synthase-2. J Biol Chem 1996; 271: 8919–8924. 10.1074/jbc.271.15.8919 CASPubMedWeb of Science®Google Scholar 117 Pratico D, Lawson JA, FitzGerald GA. Cyclooxygenase-dependent formation of the isoprostane, 8-epi prostaglandin F2 alpha. J Biol Chem 1995; 270: 9800–9808. 10.1074/jbc.270.17.9800 CASPubMedWeb of Science®Google Scholar 118 Rathaus M, Podjarny E, Pomeranz A, Green J, Bernheim J. Adriamycin-related hypertension in pregnant rats: Response to a thromboxane receptor antagonist. Clin Sci 1995; 88: 623–627. 10.1042/cs0880623 CASPubMedWeb of Science®Google Scholar 119 Raychowdhury ML, Yukawa M, Collins LJ, McGrail SH, Kent KC, Ware JA. Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A2 receptor. J Biol Chem 1994: 269: 19256–19261. 10.1016/S0021-9258(17)32161-0 CASPubMedWeb of Science®Google Scholar 120 Remuzzi G, Fitzgerald GA, Patrono C. Thromboxane synthesis and action within the kidney. Kidney Int 1992: 41: 1483–1493. 10.1038/ki.1992.217 CASPubMedWeb of Science®Google Scholar 121 Sage SO, Rink TJ. The kinetics of changes in intracellular calcium concentration in fura-2-loaded human platelets. J Biol Chem 1987: 262: 16364–16369. CASPubMedWeb of Science®Google Scholar 122 Scharschmidt L, Simonson M, Dunn MJ. Glomerular prostaglandins, angiotensin II, and nonsteroidal anti-inflammatory drugs. Am J Med 1986; 81(Suppl. 2B): 30–42. 10.1016/0002-9343(86)90906-X CASPubMedWeb of Science®Google Scholar 123 Schumacher WA, Heran CL. Effect of thromboxane receptor antagonists on venous thromboxane in rats. J Pharmacol Exp Ther 1989: 248: 1109–1115. CASPubMedWeb of Science®Google Scholar 124 Shenker A, Goldsmith P, Unson CG, Spiegel AM. The G protein coupled to the thromboxane-A2 receptor in human platelets is a member of the novel Gq family. J Biol Chem 1991; 266: 9039–9313. PubMedWeb of Science®Google Scholar 125 Shibouta Y, Terashita Z, Inada Y, Nishikawa K. Delay of the initiation of hypertension in spontaneously hypertensive rats by CV-4151, a specific thromboxane A2-synthetase inhibitor. Eur J Pharmacol 1985; 109: 135–144. 10.1016/0014-2999(85)90414-5 CASPubMedWeb of Science®Google Scholar 126 Siess W, Stifel M, Binder H, Weber PC. Activation of V1-receptors by vasopressin stimulates inositol phospholipid hydrolysis and arachidonate metabolism in human platelets. Biochem J 1986; 233: 83–91. 10.1042/bj2330083 CASPubMedWeb of Science®Google Scholar 127 Sjöberg T, Steen S. The strong contractile effect of the thromboxane receptor agonist U-46619 in isolated human pulmonary arteries and its competitive antagonism by BM-13.505. Acta Physiol Scand 1989; 136: 161–165. 10.1111/j.1748-1716.1989.tb08648.x CASPubMedWeb of Science®Google Scholar 128 Smith EF, McDonald J. Protective effects of the thromboxane receptor antagonists BM 13.177 and BM 13.505 against U46619-induced sudden death in rats. Pharmacology 1988; 36: 340–347. 10.1159/000138404 CASPubMedWeb of Science®Google Scholar 129 Smith EF, Griswold DE, Egan JW, Hillegas LM, Dimartino MJ. Reduction of myocardial damage and polymorphonuclear leukocyte accumulation following coronary occlusion and reperfusion by the thromboxane receptor antagonist BM 13.505. J Cardiovasc Pharmacol 1989: 13: 715–722. CASPubMedWeb of Science®Google Scholar 130 Smith EF, Earl CQ, Egan JW. BM 13.505, a selective thromboxane receptor antagonist, reduces myocardial infarct size following coronary artery reperfusion. Prost Leuk and Essential Fatty Acids 1989: 38: 15–23. 10.1016/0952-3278(89)90142-7 CASPubMedWeb of Science®Google Scholar 131 Smith JB, Yanagisawa A, Zipkin R, Lefer AM. Constriction of cat coronary arteries by synthetic thromboxane A2 and its antagonism. Prostaglandins 1987: 33: 777–782. 10.1016/0090-6980(87)90105-5 CASPubMedWeb of Science®Google Scholar 132 Spurney RF. Characterization of glomerular thromboxane receptors in murine lupus nephritis. J Pharmacol Exp Ther 1993; 264: 584–590. CASPubMedWeb of Science®Google Scholar 133 Staiger C, Uebis V, Kaufmann B, Brindley F, Neugebauer G. Dose-range-finding study on BM 13.505, a new thromboxane A2-receptor antagonist in healthy volunteers. Naunyn-Schmiedeberg's Arch Pharmacol 1986; 332(Suppl.):19; R385. Google Scholar 134 Stegmeier K, Pill J, Muller-Beckmann B, Sponer G, Patscheke H. Comparison of the thromboxane receptor blocker BM 13.177 and BM 13.505 in vitro and in vivo. Proc EDTA-ERA 1985; 22: 1012–1016. Google Scholar 135 Stegmeier K, Pill J, Patscheke H. BM 13.505, a selective and potent TXA2 receptor antagonist. Naunyn-Schmiedeberg's Arch Pharmacol 1986; 332(Suppl.):19; R36. Google Scholar 136 Stegmeier K, Sponer G, Pill J. Thromboxane A2 does not play a role in the development or maintenance of hypertension in spontaneously hypertensive rats. Pros Clin Res 1987: 253–257. CASGoogle Scholar 137 Swayne GTG, Maguire J, Dolan D, et al. Evidence for homogeneity of thromboxane A2 receptor using structurally different antagonists. Eur J Pharmacol 1988; 152: 311–319. 10.1016/0014-2999(88)90726-1 CASPubMedWeb of Science®Google Scholar 138 Taketo M, Rochelle JM, Sugimoto Y, et al. Mapping of the genes encoding mouse thromboxane A2 receptor and prostaglandin E receptor subtypes. EP2 and EP3 Genomics 1994: 19: 585–588. 10.1006/geno.1994.1113 CASPubMedWeb of Science®Google Scholar 139 Terres W, Kupper W, Hamm CW, Bleidfeld W. Resting myocardial ischemia after intravenous infusion of BM 13.177 (sulotroban), a thromboxane receptor antagonist. Thromb Res 1987; 48: 577–583. 10.1016/0049-3848(87)90389-6 CASPubMedWeb of Science®Google Scholar 140 Thiemermann C, Ney P, Schrör K. The thromboxane-receptor antagonist, daltroban, protects the myocardium from ischaemic injury resulting in suppression of leukocytosis. Eur J Pharmacol 1988; 155: 57–67. 10.1016/0014-2999(88)90402-5 CASPubMedWeb of Science®Google Scholar 141 Tibes U, Gerstheimer F, Luecker P, Uebis U. Pharmacokinetics and pharmacodynamics of the TxA2 receptor blocker daltroban after multiple p.o. dosing. Proc XIIth Int Congress Thromb Haemos 1989;Abst 1306. Google Scholar 142 Urbaschek R, Urbascheck B, Stegmeier K, Patscheke H. Beneficial effects of thromboxane receptor blockers in endotoxin shock. J Clin Chem Biochem 1985; 23: 574. Web of Science®Google Scholar 143 Valentin JP, Jover B, Maffre M, Bertolino F, Bessac AM, John GW. Losartan prevents thromboxane A2 prostanoid (TP) receptor–mediated increase in microvascular permeability in the rat. Am J Hypertension 1997; 10: 1058–1063. 10.1016/S0895-7061(97)00276-8 CASPubMedWeb of Science®Google Scholar 144 Verheggen R, Spoerri PE, Schrör K. Receptor-mediated changes in vessel tone of fresh and aged bovine cerebral arteries in vitro. Prost Clin Res: Cardiovasc Syst 1989: 193–198. CASGoogle Scholar 145 Verheij M, Stewart FA, Oussoren Y, Weening JJ, Dewit L. Amelioration of radiation nephropathy by acetylsalicylic acid. Int J Radiat Biol 1995; 67: 587–596. 10.1080/09553009514550701 CASPubMedWeb of Science®Google Scholar 146 Vermylen J, Deckmyn H. Thromboxane synthase inhibitors and receptor antagonists. Cardiovasc Drugs Ther 1992; 6: 29–33. 10.1007/BF00050914 CASPubMedWeb of Science®Google Scholar 147 Verstraete M. Thromboxane synthase inhibition, thromboxane/endoperoxide-receptor blockade and molecules with the dual property. Drugs Today 1993; 29: 221–232. CASGoogle Scholar 148 Viehman GE, Ma XL, Lefer AM. Daltroban, a thromboxane-receptor antagonist, protects the myocardium against reperfusion injury following myocardial ischemia without protecting the coronary endothelium. Meth Find Exp Clin Pharmacol 1990; 12: 651–656. CASPubMedWeb of Science®Google Scholar 149 Wang Z, Ciabattoni G, Créminon C, et al. Immunological characterization of urinary 8-epi-prostaglandin F2α excretion in man. J Pharmacol Exp Ther 1995; 275: 94–100. CASPubMedWeb of Science®Google Scholar 150 Watson SP, Reep B, McConnell RT, Lapetina EG. Collagen stimulates [3H]inositol trisphosphate formation in indomethacin-treated human platelets. Biochem J 1985; 226: 831–927. 10.1042/bj2260831 CASPubMedWeb of Science®Google Scholar 151 Wilkes BM. Reduced glomerular thromboxane receptor sites and vasoconstrictor responses in diabetic rats. Kidney Int 1992; 41: 992–999. 10.1038/ki.1992.151 CASPubMedWeb of Science®Google Scholar 152 Witte EC, Wolfe HP, Hagenbruch B, Stegmeier K, Pill J. 4-piperazino-benzoic acid and phenylalkkanoic acid derivatives, useful as antilipidaemics and platelet aggregation inhibitors. Eur Patent Appl. 1983;EP 0076996. Google Scholar 153 Witte EC, Wolfe HP, Stegmeier K, Roesch E. Sulphonamidophenylcarboxylic acid compounds and pharmacological compositions containing them. US Patent Appl 1984;EP 4, 443. Google Scholar 154 Yamagishi T, Yanagisawa T, Taira N. Activation of phospholipase C by the agonist U46619 is inhibited by cromakalim-induced hyperpolarization in porcine coronary artery. Biochem Biophys Res Commun 1992; 187: 1517–1522. 10.1016/0006-291X(92)90474-Y CASPubMedWeb of Science®Google Scholar 155 Yanagisawa A, Smith JA, Brezinski ME, Lefer AM. Mechanism of antagonism of thromboxane receptors in vascular smooth muscle. Eur J Pharmacol 1987; 133: 89–96. 10.1016/0014-2999(87)90209-3 CASPubMedWeb of Science®Google Scholar 156 Yoshimura K, Tod ML, Pier KG, Rubin LJ. Role of venoconstriction in thromboxane-induced pulmonary hypertension and edema in lambs. J Appl Physiol 1989; 66: 929–935. CASPubMedWeb of Science®Google Scholar 157 Zenser TV, Herman CA, Gorman RR, Davis BB. Metabolism and action of the prostaglandin endoperoxide PGH2 in the rat kidney. Biochem Biophys Res Commun 1977; 70: 357–363. 10.1016/0006-291X(77)90165-6 Web of Science®Google Scholar Citing Literature Volume16, Issue3September 1998Pages 264-287 ReferencesRelatedInformation
Referência(s)